[Oligorecurrent prostate cancer: current management and perspectives].
Oligometastatic prostate cancer (PCa) is an intense area of research thanks to the development of novel PET tracers such as 18F-choline or 68Ga-PSMA. Several retrospective studies in patients with hormone-sensitive oligorecurrent PCa (usually up to 5 metastases with a controlled primary tumor)…
- Ref: doi: 10.1016/S0007-4551(20)30276-9.
- Année de publication : 2020
- Auteurs : Loubersac T, Guimas V, Rio E, Libois V, Rigaud J, Supiot S.
- Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »